Abivax moved to calm investor concern over its ulcerative colitis candidate obefazimod by disclosing additional safety data, indicating cancer cases in a Phase 3 setting were within the expected range for the trial population. The update follows a period when new cancer reports triggered a sharp stock selloff. Analysts and investors are watching whether the safety signal can be contained well enough to support ongoing regulatory and commercial expectations. The company’s messaging frames the new data as consistent with what would be expected for these patients. For biotech leaders, the development underscores how quickly safety interpretations can swing sentiment in late-stage inflammatory disease programs—and how fast companies must deliver credible follow-up datasets.